Therapy Areas: Infectious Diseases
Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines
28 July 2021 - - US-based development-stage company Oragenics, Inc. (NYSE American: OGEN) has entered into a licensing agreement with the National Research Council of Canada that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants, the company said.

The NRC technologies, in combination with the US National Institutes of Health elements found in the company's Terra CoV-2 vaccine, provide Oragenics with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern.

This platform should allow production of cell lines within six to eight weeks of spike gene sequence availability, compared with six to nine months for traditional production of such cell lines.

The NRC technologies, developed with support from the NRC's Pandemic Response Challenge Program, will expedite the evaluation of SARS-CoV-2 antigen candidates in preclinical and clinical studies.

Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms.

Its lead product is Terra CoV-2, a vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus.

The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on addressing supply-chain challenges, and offering more patient-friendly administration, such as intranasal.

Its antibiotics program features a novel class of antibiotics against infectious diseases that have developed resistance to commercial antibiotics.
Login
Username:

Password: